Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
More News related to AMRI
- Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
- AMRI Announces Third Quarter 2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
- AMRI to Present at the Oppenheimer 20th Annual Healthcare Conference
Albany Molecular Research (NASDAQ: AMRI) reports Q3 loss of $0.02, 2 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $47.70 million, which compares to the estimate of $46.27 million.
Sees Q409 revs of $32 - $36 million, and FY09 revs of $154 - $158 million. Consensus sees $47.93 million and $199.54 million, respectively.
Also sees Q409 loss of $0.06 - $0.10, and FY09 loss of $0.01 - $0.05. Consensus sees ($0.03) and $0.05 respectively.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
